BodeVet, Inc., a Maryland-based company focused on the development of novel blood products for use in veterinary transfusion, announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the company a 2-year contract valued at $1.7 million to conduct a clinical trial in canine polytrauma patients at veterinary critical care hospitals. The study is designed to evaluate the administration of two lyophilized blood products, StablePlate RX® Canine (lyophilized canine platelets) and StablePlas™ Canine (lyophilized canine plasma) and their effects on hemodynamic stabilization following trauma, and to determine survival benefit when compared to current veterinary standard of care for trauma resuscitation.
-
About this Post
- Title: Cellphire Subsidiary, BodeVet, Inc., Awarded $1.7 Million U.S. Army Contract
- Posted: June 5th, 2020
- Author: Rob Woods
- Filed Under: Uncategorized
-
Recent Posts
- Cellphire President G. Michael Fitzpatrick Awarded Armed Services Program Lifetime Achievement Award
- Cellphire Subsidiary, BodeVet, Inc., Awarded $1.7 Million U.S. Army Contract
- Cellphire Announces Orphan Drug Designation of Thrombosomes® for Treatment of Acute Radiation Syndrome
- Cellphire Announces Exercise by BARDA of Option 3 of Contract to Develop Platelet-Based Hemostatic
- Cellphire Begins Phase 2 Trial of Thrombosomes® in Bleeding Thrombocytopenic Patients
-
Categories
- No categories
-
Archives